SEATTLE GENETICS INC's ticker is SGENXXXX and the CUSIP is 812578102. A total of 219 filers reported holding SEATTLE GENETICS INC in Q2 2016. The put-call ratio across all filers is 0.60 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $29,668,000 | +35.2% | 151,607 | +17.4% | 0.14% | +17.1% |
| Q2 2020 | $21,941,000 | +72.1% | 129,128 | +16.9% | 0.12% | +27.2% |
| Q1 2020 | $12,748,000 | -27.1% | 110,489 | -27.8% | 0.09% | +13.6% |
| Q4 2019 | $17,497,000 | +320.6% | 153,132 | +214.4% | 0.08% | +252.2% |
| Q3 2019 | $4,160,000 | +19.8% | 48,707 | -2.9% | 0.02% | +9.5% |
| Q2 2019 | $3,472,000 | -20.6% | 50,159 | -16.0% | 0.02% | -19.2% |
| Q1 2019 | $4,371,000 | +34.3% | 59,679 | +3.9% | 0.03% | +13.0% |
| Q4 2018 | $3,254,000 | -38.4% | 57,434 | -16.2% | 0.02% | -36.1% |
| Q3 2018 | $5,284,000 | +15.3% | 68,511 | -0.7% | 0.04% | +16.1% |
| Q2 2018 | $4,582,000 | +15.6% | 69,018 | -8.9% | 0.03% | +19.2% |
| Q1 2018 | $3,965,000 | -7.5% | 75,747 | -5.5% | 0.03% | -13.3% |
| Q4 2017 | $4,288,000 | -4.9% | 80,142 | -3.3% | 0.03% | -26.8% |
| Q3 2017 | $4,507,000 | +15.7% | 82,843 | +10.0% | 0.04% | +5.1% |
| Q2 2017 | $3,895,000 | -20.7% | 75,284 | -3.6% | 0.04% | -23.5% |
| Q1 2017 | $4,910,000 | -2.0% | 78,114 | -17.7% | 0.05% | -7.3% |
| Q4 2016 | $5,008,000 | +1.0% | 94,895 | +3.3% | 0.06% | -20.3% |
| Q3 2016 | $4,959,000 | +13.7% | 91,821 | -14.9% | 0.07% | +23.2% |
| Q2 2016 | $4,361,000 | +17.4% | 107,917 | +1.9% | 0.06% | +9.8% |
| Q1 2016 | $3,716,000 | -28.7% | 105,911 | -8.8% | 0.05% | -19.0% |
| Q4 2015 | $5,215,000 | +36.0% | 116,188 | +16.8% | 0.06% | +16.7% |
| Q3 2015 | $3,835,000 | -24.8% | 99,463 | -5.5% | 0.05% | -23.9% |
| Q2 2015 | $5,097,000 | +36.8% | 105,301 | -0.1% | 0.07% | +61.4% |
| Q1 2015 | $3,725,000 | +32.6% | 105,371 | +20.5% | 0.04% | +33.3% |
| Q4 2014 | $2,810,000 | +12.2% | 87,461 | +29.8% | 0.03% | 0.0% |
| Q3 2014 | $2,505,000 | -17.8% | 67,386 | -15.4% | 0.03% | -15.4% |
| Q2 2014 | $3,048,000 | -32.2% | 79,678 | -19.2% | 0.04% | -30.4% |
| Q1 2014 | $4,493,000 | +95.9% | 98,627 | +71.5% | 0.06% | +64.7% |
| Q4 2013 | $2,294,000 | +13.7% | 57,513 | +25.0% | 0.03% | -29.2% |
| Q3 2013 | $2,017,000 | -26.7% | 46,008 | -47.4% | 0.05% | -11.1% |
| Q2 2013 | $2,753,000 | – | 87,493 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Baker Brothers Advisors | 51,049,760 | $3,738,884,000 | 23.93% |
| Lagoda Investment Management, L.P. | 76,873 | $5,630,000 | 7.16% |
| Matrix Capital Management Company, LP | 3,141,852 | $230,109,000 | 6.14% |
| DOMINI IMPACT INVESTMENTS LLC | 3,120 | $229,000 | 3.51% |
| Opus Point Partners Management, LLC | 17,832 | $1,306,000 | 1.77% |
| Capital International Sarl | 188,200 | $13,784,000 | 1.72% |
| EMORY UNIVERSITY | 33,368 | $2,444,000 | 1.72% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 60,900 | $4,460,000 | 1.65% |
| CAPITAL GUARDIAN TRUST CO | 1,358,254 | $99,415,000 | 1.32% |
| Rhenman & Partners Asset Management AB | 150,598 | $11,030,000 | 1.29% |